Download PDF
Semin Thromb Hemost 2011; 37(4): 362-374
DOI: 10.1055/s-0031-1276585
© Thieme Medical Publishers

C1-Inhibitor: More Than a Serine Protease Inhibitor

Sacha Zeerleder1
  • 1Department of Immunopathology, Sanquin Research and Landsteiner Laboratory of the AMC, Amsterdam, The Netherlands and Department of Hematology, Academic Medical Center, University of Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
30 July 2011 (online)

    Permissions and Reprints

ABSTRACT

C1-inhibitor (C1-inh) is a crucial regulator of the activation of plasmatic cascade systems involved in inflammation contributing to the homeostasis in the generation of proinflammatory mediators. The importance of C1-inh is illustrated by patients with hereditary angioedema where decreased levels of C1-inh lead to an uncontrolled generation of vasoactive peptides resulting in potential life-threatening subcutaneous edema. Recent publications, however, suggest that the anti-inflammatory properties of C1-inh do not strictly depend on its capacity to regulate the complement and contact phase system. This review summarizes the biochemical characteristics of C1-inh and its role in the regulation of plasmatic cascade systems as well as the role of the nonserpin domain.

KEYWORDS

C1-inhibitor - hereditary angioedema - serpin - contact phase - complement - sepsis

REFERENCES

  • 1 Caliezi C, Wuillemin W A, Zeerleder S, Redondo M, Eisele B, Hack C E. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.  Pharmacol Rev. 2000;  52 (1) 91-112
    PubMedGoogle Scholar
  • 2 Schapira M, de Agostini A, Schifferli J A, Colman R W. Biochemistry and pathophysiology of human C1 inhibitor: current issues.  Complement. 1985;  2 (2–3) 111-126
    PubMedGoogle Scholar
  • 3 Nuijens J H, Eerenberg-Belmer A JM, Huijbregts C C et al.. Proteolytic inactivation of plasma C1-inhibitor in sepsis.  J Clin Invest. 1989;  84 (2) 443-450
    CrossrefPubMedGoogle Scholar
  • 4 Travis J, Salvesen G S. Human plasma proteinase inhibitors.  Annu Rev Biochem. 1983;  52 655-709
    CrossrefPubMedGoogle Scholar
  • 5 Carrell R W, Boswell D R. Serpins: the superfamily of plasma proteinase inhibitors. In: Barrett A J, Salvesen G, eds. Proteinase Inhibitors. Amsterdam, The Netherlands: Elsevier; 1990: 403-420
    Google Scholar
  • 6 Carrell R W, Travis J. α1-antitrypsin and the serpins: variation and countervariation.  Trends Biochem Sci. 1985;  10 20-24
    CrossrefPubMedGoogle Scholar
  • 7 Carter P E, Dunbar B, Fothergill J E. Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins.  Eur J Biochem. 1988;  173 (1) 163-169
    CrossrefPubMedGoogle Scholar
  • 8 Coutinho M, Aulak K S, Davis III A E. Functional analysis of the serpin domain of C1 inhibitor.  J Immunol. 1994;  153 (8) 3648-3654
    PubMedGoogle Scholar
  • 9 Wagenaar-Bos I G, Hack C E. Structure and function of C1-inhibitor.  Immunol Allergy Clin North Am. 2006;  26 (4) 615-632
    CrossrefPubMedGoogle Scholar
  • 10 Bock S C, Skriver K, Nielsen E et al.. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization.  Biochemistry. 1986;  25 (15) 4292-4301
    CrossrefPubMedGoogle Scholar
  • 11 Bos I G, Lubbers Y T, Roem D, Abrahams J P, Hack C E, Eldering E. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.  J Biol Chem. 2003;  278 (32) 29463-29470
    CrossrefPubMedGoogle Scholar
  • 12 Huntington J A, Read R J, Carrell R W. Structure of a serpin-protease complex shows inhibition by deformation.  Nature. 2000;  407 (6806) 923-926
    CrossrefPubMedGoogle Scholar
  • 13 Schapira M, de Agostini A, Colman R W. C1 inhibitor: the predominant inhibitor of plasma kallikrein.  Methods Enzymol. 1988;  163 179-185
    PubMedGoogle Scholar
  • 14 Ravindran S, Grys T E, Welch R A, Schapira M, Patston P A. Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor.  Thromb Haemost. 2004;  92 (6) 1277-1283
    PubMedGoogle Scholar
  • 15 Minta J O. The role of sialic acid in the functional activity and the hepatic clearance of C1-INH.  J Immunol. 1981;  126 (1) 245-249
    PubMedGoogle Scholar
  • 16 Reboul A, Prandini M H, Colomb M G. Proteolysis and deglycosylation of human C1 inhibitor. Effect on functional properties.  Biochem J. 1987;  244 (1) 117-121
    PubMedGoogle Scholar
  • 17 van Doorn M B, Burggraaf J, van Dam T et al.. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema.  J Allergy Clin Immunol. 2005;  116 (4) 876-883
    CrossrefPubMedGoogle Scholar
  • 18 Bos I G, de Bruin E C, Karuntu Y A, Modderman P W, Eldering E, Hack C E. Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor.  Biochim Biophys Acta. 2003;  1648 (1–2) 75-83
    PubMedGoogle Scholar
  • 19 Bensa J C, Reboul A, Colomb M G. Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes.  Biochem J. 1983;  216 (2) 385-392
    PubMedGoogle Scholar
  • 20 Yeung Laiwah A C, Jones L, Hamilton A O, Whaley K. Complement-subcomponent-C1-inhibitor synthesis by human monocytes.  Biochem J. 1985;  226 (1) 199-205
    PubMedGoogle Scholar
  • 21 Katz Y, Strunk R C. Synthesis and regulation of C1 inhibitor in human skin fibroblasts.  J Immunol. 1989;  142 (6) 2041-2045
    PubMedGoogle Scholar
  • 22 Katz Y, Gur S, Aladjem M, Strunk R C. Synthesis of complement proteins in amnion.  J Clin Endocrinol Metab. 1995;  80 (7) 2027-2032
    CrossrefPubMedGoogle Scholar
  • 23 Walker D G, Yasuhara O, Patston P A, McGeer E G, McGeer P L. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease.  Brain Res. 1995;  675 (1–2) 75-82
    CrossrefPubMedGoogle Scholar
  • 24 Lotz M, Zuraw B L. Interferon-gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes.  J Immunol. 1987;  139 (10) 3382-3387
    PubMedGoogle Scholar
  • 25 Zuraw B L, Lotz M. Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma.  J Biol Chem. 1990;  265 (21) 12664-12670
    PubMedGoogle Scholar
  • 26 Schmidt B, Gyapay G, Válay M, Füst G. Human recombinant macrophage colony-stimulating factor (M-CSF) increases Cl-esterase inhibitor (Cl-INH) synthesis by human monocytes.  Immunology. 1991;  74 (4) 677-679
    PubMedGoogle Scholar
  • 27 Heda G D, Mardente S, Weiner L, Schmaier A H. Interferon γ increases in vitro and in vivo expression of C1 inhibitor.  Blood. 1990;  75 (12) 2401-2407
    PubMedGoogle Scholar
  • 28 Heda G D, Kehoe K J, Mahdi F, Schmaier A H. Phosphatase 2A participates in interferon-γ's induced upregulation of C1 inhibitor mRNA expression.  Blood. 1996;  87 (7) 2831-2838
    PubMedGoogle Scholar
  • 29 Zahedi K, Prada A E, Prada J A, Davis III A E. Characterization of the IFN-γ-responsive element in the 5′ flanking region of the C1 inhibitor gene.  J Immunol. 1997;  159 (12) 6091-6096
    PubMedGoogle Scholar
  • 30 Schmaier A H, Amenta S, Xiong T, Heda G D, Gewirtz A M. Expression of platelet C1 inhibitor.  Blood. 1993;  82 (2) 465-474
    CrossrefPubMedGoogle Scholar
  • 31 Woo P, Lachmann P JL, Harrison R A, Amos N, Cooper C, Rosen F S. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases.  Clin Exp Immunol. 1985;  61 (1) 1-8
    PubMedGoogle Scholar
  • 32 Quastel M, Harrison R, Cicardi M, Alper C A, Rosen F S. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema.  J Clin Invest. 1983;  71 (4) 1041-1046
    CrossrefPubMedGoogle Scholar
  • 33 de Smet BJGL, de Boer J P, Agterberg J, Rigter G, Bleeker W K, Hack C E. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats.  Blood. 1993;  81 (1) 56-61
    PubMedGoogle Scholar
  • 34 Pappalardo E, Zingale L C, Cicardi M. C1 inhibitor gene expression in patients with hereditary angioedema: quantitative evaluation by means of real-time RT-PCR.  J Allergy Clin Immunol. 2004;  114 (3) 638-644
    CrossrefPubMedGoogle Scholar
  • 35 Wuillemin W A, Bleeker W K, Agterberg J, Rigter G, ten Cate H, Hack C E. Clearance of human factor XIa-inhibitor complexes in rats.  Br J Haematol. 1996;  93 (4) 950-954
    CrossrefPubMedGoogle Scholar
  • 36 Nuijens J H, Huijbregts C C, Eerenberg-Belmer A JM et al.. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis.  Blood. 1988;  72 (6) 1841-1848
    PubMedGoogle Scholar
  • 37 Perlmutter D H, Glover G I, Rivetna M, Schasteen C S, Fallon R J. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes.  Proc Natl Acad Sci U S A. 1990;  87 (10) 3753-3757
    CrossrefPubMedGoogle Scholar
  • 38 Pizzo S V, Mast A E, Feldman S R, Salvesen G. In vivo catabolism of α 1-antichymotrypsin is mediated by the Serpin receptor which binds α 1-proteinase inhibitor, antithrombin III and heparin cofactor II.  Biochim Biophys Acta. 1988;  967 (2) 158-162
    CrossrefPubMedGoogle Scholar
  • 39 Kalter E S, Daha M R, ten Cate J W, Verhoef J, Bouma B N. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock.  J Infect Dis. 1985;  151 (6) 1019-1027
    CrossrefPubMedGoogle Scholar
  • 40 Falus A, Rokita H, Walcz E, Brozik M, Hidvégi T, Merétey K. Hormonal regulation of complement biosynthesis in human cell lines—II. Upregulation of the biosynthesis of complement components C3, factor B and C1 inhibitor by interleukin-6 and interleukin-1 in human hepatoma cell line.  Mol Immunol. 1990;  27 (2) 197-201
    CrossrefPubMedGoogle Scholar
  • 41 Brower M S, Harpel P C. Proteolytic cleavage and inactivation of α 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.  J Biol Chem. 1982;  257 (16) 9849-9854
    PubMedGoogle Scholar
  • 42 Eldering E, Huijbregts C CM, Nuijens J H, Verhoeven A J, Hack C E. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.  J Clin Invest. 1993;  91 (3) 1035-1043
    CrossrefPubMedGoogle Scholar
  • 43 Leid R W, Ballieux BEPB, van der Heijden I et al.. Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3.  Eur J Immunol. 1993;  23 (11) 2939-2944
    CrossrefPubMedGoogle Scholar
  • 44 Wallace E M, Perkins S J, Sim R B, Willis A C, Feighery C, Jackson J. Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes.  Mol Med. 1997;  3 (6) 385-396
    PubMedGoogle Scholar
  • 45 Catanese J, Kress L F. Enzymatic inactivation of human plasma C1-inhibitor and α 1-antichymotrypsin by Pseudomonas aeruginosa proteinase and elastase.  Biochim Biophys Acta. 1984;  789 (1) 37-43
    CrossrefPubMedGoogle Scholar
  • 46 Zhang F, Bries A D, Lang S C et al.. Metabolic alteration of the N-glycan structure of a protein from patients with a heterozygous protein deficiency.  Biochim Biophys Acta. 2004;  1739 (1) 43-49
    PubMedGoogle Scholar
  • 47 Doekes G, van Es L A, Daha M R. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.  Immunology. 1983;  49 (2) 215-222
    PubMedGoogle Scholar
  • 48 Tenner A J, Frank M M. Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1.  J Immunol. 1986;  137 (2) 625-630
    PubMedGoogle Scholar
  • 49 Turner M W. Mannose-binding lectin: the pluripotent molecule of the innate immune system.  Immunol Today. 1996;  17 (11) 532-540
    CrossrefPubMedGoogle Scholar
  • 50 Thiel S, Vorup-Jensen T, Stover C M et al.. A second serine protease associated with mannan-binding lectin that activates complement.  Nature. 1997;  386 (6624) 506-510
    CrossrefPubMedGoogle Scholar
  • 51 Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease.  J Exp Med. 1992;  176 (6) 1497-1502
    CrossrefPubMedGoogle Scholar
  • 52 Matsushita M, Thiel S, Jensenius J C, Terai I, Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease.  J Immunol. 2000;  165 (5) 2637-2642
    PubMedGoogle Scholar
  • 53 Makrides S C. Therapeutic inhibition of the complement system.  Pharmacol Rev. 1998;  50 (1) 59-87
    PubMedGoogle Scholar
  • 54 Podack E R, Kolb W P, Müller-Eberhard H J. The SC5b-7 complex: formation, isolation, properties, and subunit composition.  J Immunol. 1977;  119 (6) 2024-2029
    PubMedGoogle Scholar
  • 55 Tschopp J, Müller-Eberhard H J, Podack E R. Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9.  Nature. 1982;  298 (5874) 534-538
    CrossrefPubMedGoogle Scholar
  • 56 Hugli T E, Müller-Eberhard H J. Anaphylatoxins: C3a and C5a.  Adv Immunol. 1978;  26 1-53
    PubMedGoogle Scholar
  • 57 Morgan E L. Modulation of the immune response by anaphylatoxins.  Complement. 1986;  3 (3) 128-136
    PubMedGoogle Scholar
  • 58 Hartmann K, Henz B M, Krüger-Krasagakes S et al.. C3a and C5a stimulate chemotaxis of human mast cells.  Blood. 1997;  89 (8) 2863-2870
    PubMedGoogle Scholar
  • 59 Gerard C, Gerard N P. C5A anaphylatoxin and its seven transmembrane-segment receptor.  Annu Rev Immunol. 1994;  12 775-808
    CrossrefPubMedGoogle Scholar
  • 60 Sim R B, Reboul A, Arlaud G J, Villiers C L, Colomb M G. Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma.  FEBS Lett. 1979;  97 (1) 111-115
    CrossrefPubMedGoogle Scholar
  • 61 Liszewski M K, Farries T C, Lublin D M, Rooney I A, Atkinson J P. Control of the complement system.  Adv Immunol. 1996;  61 201-283
    PubMedGoogle Scholar
  • 62 Bianchino A C, Poon P H, Schumaker V N. A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor.  J Immunol. 1988;  141 (11) 3930-3936
    PubMedGoogle Scholar
  • 63 Harpel P C, Cooper N R. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.  J Clin Invest. 1975;  55 (3) 593-604
    CrossrefPubMedGoogle Scholar
  • 64 Reboul A, Arlaud G J, Sim R B, Colomb M G. A simplified procedure for the purification of C1-inactivator from human plasma. Interaction with complement subcomponents C1r and C1s.  FEBS Lett. 1977;  79 (1) 45-50
    CrossrefPubMedGoogle Scholar
  • 65 Salvesen G S, Catanese J J, Kress L F, Travis J. Primary structure of the reactive site of human C1-inhibitor.  J Biol Chem. 1985;  260 (4) 2432-2436
    PubMedGoogle Scholar
  • 66 Arlaud G J, Reboul A, Sim R B, Colomb M G. Interaction of C1-inhibitor with the C1r and C1s subcomponents in human C1.  Biochim Biophys Acta. 1979;  576 (1) 151-162
    PubMedGoogle Scholar
  • 67 Ziccardi R J, Cooper N R. Active disassembly of the first complement component, C-1, by C-1 inactivator.  J Immunol. 1979;  123 (2) 788-792
    PubMedGoogle Scholar
  • 68 Chesne S, Villiers C L, Arlaud G J, Lacroix M B, Colomb M G. Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1.  Biochem J. 1982;  201 (1) 61-70
    PubMedGoogle Scholar
  • 69 Sim R B, Arlaud G J, Colomb M G. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s.  Biochim Biophys Acta. 1980;  612 (2) 433-449
    PubMedGoogle Scholar
  • 70 Jiang H, Wagner E, Zhang H, Frank M M. Complement 1 inhibitor is a regulator of the alternative complement pathway.  J Exp Med. 2001;  194 (11) 1609-1616
    CrossrefPubMedGoogle Scholar
  • 71 Kaplan A P, Silverberg M. The coagulation-kinin pathway of human plasma.  Blood. 1987;  70 (1) 1-15
    CrossrefPubMedGoogle Scholar
  • 72 Colman R W. Surface-mediated defense reactions. The plasma contact activation system.  J Clin Invest. 1984;  73 (5) 1249-1253
    CrossrefPubMedGoogle Scholar
  • 73 Cochrane C G, Griffin J H. The biochemistry and pathophysiology of the contact system of plasma.  Adv Immunol. 1982;  33 241-306
    PubMedGoogle Scholar
  • 74 Hojima Y, Cochrane C G, Wiggins R C, Austen K F, Stevens R L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E.  Blood. 1984;  63 (6) 1453-1459
    PubMedGoogle Scholar
  • 75 Kannemeier C, Shibamiya A, Nakazawa F et al.. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation.  Proc Natl Acad Sci U S A. 2007;  104 (15) 6388-6393
    CrossrefPubMedGoogle Scholar
  • 76 Maas C, Govers-Riemslag J W, Bouma B et al.. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.  J Clin Invest. 2008;  118 (9) 3208-3218
    PubMedGoogle Scholar
  • 77 Müller F, Mutch N J, Schenk W A et al.. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.  Cell. 2009;  139 (6) 1143-1156
    CrossrefPubMedGoogle Scholar
  • 78 Herwald H, Mörgelin M, Olsén A et al.. Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseases.  Nat Med. 1998;  4 (3) 298-302
    CrossrefPubMedGoogle Scholar
  • 79 Colman R W, Bagdasarian A, Talamo R C et al.. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.  J Clin Invest. 1975;  56 (6) 1650-1662
    CrossrefPubMedGoogle Scholar
  • 80 Ghebrehiwet B, Randazzo B P, Dunn J T, Silverberg M, Kaplan A P. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.  J Clin Invest. 1983;  71 (5) 1450-1456
    CrossrefPubMedGoogle Scholar
  • 81 Schousboe I. Binding of activated factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor.  Eur J Biochem. 2003;  270 (1) 111-118
    PubMedGoogle Scholar
  • 82 Lämmle B, Wuillemin W A, Huber I et al.. Thromboembolism and bleeding tendency in congenital factor XII deficiency—a study on 74 subjects from 14 Swiss families.  Thromb Haemost. 1991;  65 (2) 117-121
    PubMedGoogle Scholar
  • 83 Pixley R A, De La Cadena R, Page J D et al.. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons.  J Clin Invest. 1993;  91 (1) 61-68
    CrossrefPubMedGoogle Scholar
  • 84 Gailani D, Broze Jr G J. Factor XI activation in a revised model of blood coagulation.  Science. 1991;  253 (5022) 909-912
    CrossrefPubMedGoogle Scholar
  • 85 Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces.  J Biol Chem. 1991;  266 (12) 7353-7358
    PubMedGoogle Scholar
  • 86 Renné T, Pozgajová M, Grüner S et al.. Defective thrombus formation in mice lacking coagulation factor XII.  J Exp Med. 2005;  202 (2) 271-281
    CrossrefPubMedGoogle Scholar
  • 87 Wuillemin W A, Minnema M, Meijers J C et al.. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor.  Blood. 1995;  85 (6) 1517-1526
    PubMedGoogle Scholar
  • 88 Wuillemin W A, Hack C E, Bleeker W K, Biemond B J, Levi M, ten Cate H. Inactivation of factor Xia in vivo: studies in chimpanzees and in humans.  Thromb Haemost. 1996;  76 (4) 549-555
    PubMedGoogle Scholar
  • 89 Nielsen E W, Morrissey J, Olsen J O, Osterud B. Factor VIIa in patients with C1-inhibitor deficiency.  Thromb Haemost. 1995;  74 (4) 1103-1106
    PubMedGoogle Scholar
  • 90 Nielsen E W, Johansen H T, Høgåsen K, Wuillemin W A, Hack C E, Mollnes T E. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema.  Scand J Immunol. 1996;  44 (2) 185-192
    CrossrefPubMedGoogle Scholar
  • 91 Husain S S, Hasan A AK, Budzynski A Z. Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots.  Blood. 1989;  74 (3) 999-1006
    PubMedGoogle Scholar
  • 92 Vassalli J D, Sappino A P, Belin D. The plasminogen activator/plasmin system.  J Clin Invest. 1991;  88 (4) 1067-1072
    CrossrefPubMedGoogle Scholar
  • 93 Zamarron C, Lijnen H R, Van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase—I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.  Thromb Haemost. 1984;  52 (1) 19-23
    PubMedGoogle Scholar
  • 94 Schmaier A H. Contact activation: a revision.  Thromb Haemost. 1997;  78 (1) 101-107
    PubMedGoogle Scholar
  • 95 Schousboe I. Factor XIIa activation of plasminogen is enhanced by contact activating surfaces and Zn2+.  Blood Coagul Fibrinolysis. 1997;  8 (2) 97-104
    CrossrefPubMedGoogle Scholar
  • 96 Levi M, Hack C E, de Boer J P, Brandjes D P, Büller H R, ten Cate J W. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo.  J Clin Invest. 1991;  88 (4) 1155-1160
    CrossrefPubMedGoogle Scholar
  • 97 Zeerleder S, Schloesser M, Redondo M et al.. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency—a study on 73 subjects from 14 Swiss families.  Thromb Haemost. 1999;  82 (4) 1240-1246
    PubMedGoogle Scholar
  • 98 Huisman L GM, van Griensven J MT, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma.  Thromb Haemost. 1995;  73 (3) 466-471
    PubMedGoogle Scholar
  • 99 Levi M, Roem D, Kamp A M, de Boer J P, Hack C E, ten Cate J W. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.  Thromb Haemost. 1993;  69 (2) 141-146
    PubMedGoogle Scholar
  • 100 Römisch J, Feussner A, Vermöhlen S, Stöhr H A. A protease isolated from human plasma activating factor VII independent of tissue factor.  Blood Coagul Fibrinolysis. 1999;  10 (8) 471-479
    CrossrefPubMedGoogle Scholar
  • 101 Römisch J, Vermöhlen S, Feussner A, Stöhr H. The FVII activating protease cleaves single-chain plasminogen activators.  Haemostasis. 1999;  29 (5) 292-299
    PubMedGoogle Scholar
  • 102 Etscheid M, Hunfeld A, König H, Seitz R, Dodt J. Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism.  Biol Chem. 2000;  381 (12) 1223-1231
    CrossrefPubMedGoogle Scholar
  • 103 Muhl L, Galuska S P, Oörni K et al.. High negative charge-to-size ratio in polyphosphates and heparin regulates factor VII-activating protease.  FEBS J. 2009;  276 (17) 4828-4839
    CrossrefPubMedGoogle Scholar
  • 104 Nakazawa F, Kannemeier C, Shibamiya A et al.. Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP).  Biochem J. 2005;  385 (Pt 3) 831-838
    CrossrefPubMedGoogle Scholar
  • 105 Yamamichi S, Nishitani M, Nishimura N, Matsushita Y, Hasumi K. Polyamine-promoted autoactivation of plasma hyaluronan-binding protein.  J Thromb Haemost. 2010;  8 (3) 559-566
    CrossrefPubMedGoogle Scholar
  • 106 Kannemeier C, Feussner A, Stöhr H A, Weisse J, Preissner K T, Römisch J. Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme.  Eur J Biochem. 2001;  268 (13) 3789-3796
    CrossrefPubMedGoogle Scholar
  • 107 Etscheid M, Beer N, Fink E, Seitz R, Johannes D. The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin.  Biol Chem. 2002;  383 (10) 1633-1643
    CrossrefPubMedGoogle Scholar
  • 108 Zeerleder S, Zwart B, te Velthuis H et al.. A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells.  FEBS Lett. 2007;  581 (28) 5382-5388
    CrossrefPubMedGoogle Scholar
  • 109 Zeerleder S, Zwart B, te Velthuis H et al.. Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP).  FASEB J. 2008;  22 (12) 4077-4084
    CrossrefPubMedGoogle Scholar
  • 110 Kannemeier C, Al-Fakhri N, Preissner K T, Kanse S M. Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells.  FASEB J. 2004;  18 (6) 728-730
    PubMedGoogle Scholar
  • 111 Sedding D, Daniel J M, Muhl L et al.. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation.  J Exp Med. 2006;  203 (13) 2801-2807
    CrossrefPubMedGoogle Scholar
  • 112 Choi-Miura N H, Takahashi K, Yoda M, Saito K, Mazda T, Tomita M. Proteolytic activation and inactivation of the serine protease activity of plasma hyaluronan binding protein.  Biol Pharm Bull. 2001;  24 (5) 448-452
    CrossrefPubMedGoogle Scholar
  • 113 Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation.  J Biol Chem. 1994;  269 (23) 15957-15960
    PubMedGoogle Scholar
  • 114 Caughman G B, Boackle R J, Vesely J. A postulated mechanism for heparin's potentiation of C1 inhibitor function.  Mol Immunol. 1982;  19 (2) 287-295
    CrossrefPubMedGoogle Scholar
  • 115 Lennick M, Brew S A, Ingham K C. Kinetics of interaction of C1 inhibitor with complement C1s.  Biochemistry. 1986;  25 (13) 3890-3898
    CrossrefPubMedGoogle Scholar
  • 116 Nilsson T, Wiman B. Kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s.  Eur J Biochem. 1983;  129 (3) 663-667
    PubMedGoogle Scholar
  • 117 Pixley R A, Schmaier A, Colman R W. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor.  Arch Biochem Biophys. 1987;  256 (2) 490-498
    CrossrefPubMedGoogle Scholar
  • 118 Rent R, Myhrman R, Fiedel B A, Gewurz H. Potentiation of C1 esterase inhibitor activity by heparin.  Clin Exp Immunol. 1976;  23 264-271
    PubMedGoogle Scholar
  • 119 Wuillemin W A, te Velthuis H, Lubbers Y T, de Ruig C P, Eldering E, Hack C E. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma.  J Immunol. 1997;  159 (4) 1953-1960
    PubMedGoogle Scholar
  • 120 Bos I G, van Mierlo G J, Bleeker W K et al.. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.  Int Immunopharmacol. 2001;  1 (8) 1583-1595
    CrossrefPubMedGoogle Scholar
  • 121 Caldwell E E, Andreasen A M, Blietz M A et al.. Heparin binding and augmentation of C1 inhibitor activity.  Arch Biochem Biophys. 1999;  361 (2) 215-222
    CrossrefPubMedGoogle Scholar
  • 122 Wuillemin W A, Eldering E, Citarella F, de Ruig C P, ten Cate H, Hack C E. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa.  J Biol Chem. 1996;  271 (22) 12913-12918
    CrossrefPubMedGoogle Scholar
  • 123 Mauron T, Lämmle B, Wuillemin W A. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins.  Thromb Haemost. 1998;  80 (1) 82-86
    PubMedGoogle Scholar
  • 124 Zeerleder S, Caliezi C, van Mierlo G et al.. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis.  Clin Diagn Lab Immunol. 2003;  10 (4) 529-535
    CrossrefPubMedGoogle Scholar
  • 125 Jansen P M, Eisele B, de Jong I W et al.. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock.  J Immunol. 1998;  160 (1) 475-484
    PubMedGoogle Scholar
  • 126 Caliezi C, Zeerleder S, Redondo M et al.. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction.  Crit Care Med. 2002;  30 (8) 1722-1728
    CrossrefPubMedGoogle Scholar
  • 127 Cai S, Dole V S, Bergmeier W et al.. A direct role for C1 inhibitor in regulation of leukocyte adhesion.  J Immunol. 2005;  174 (10) 6462-6466
    PubMedGoogle Scholar
  • 128 Liu D, Cai S, Gu X, Scafidi J, Wu X, Davis III A E. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide.  J Immunol. 2003;  171 (5) 2594-2601
    PubMedGoogle Scholar
  • 129 Liu D, Lu F, Qin G, Fernandes S M, Li J, Davis III A E. C1 inhibitor-mediated protection from sepsis.  J Immunol. 2007;  179 (6) 3966-3972
    PubMedGoogle Scholar
  • 130 Zhang H, Li J, Barrington R A, Liang G, Qin G, Liu D X. An anti-endotoxin peptide that generates from the amino-terminal domain of complement regulatory protein C1 inhibitor.  Biochem Biophys Res Commun. 2007;  359 (2) 285-291
    CrossrefPubMedGoogle Scholar
  • 131 Liu D, Gu X, Scafidi J, Davis III A E. N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice.  Infect Immun. 2004;  72 (4) 1946-1955
    CrossrefPubMedGoogle Scholar
  • 132 Liu D, Cramer C C, Scafidi J, Davis III A E. N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A.  Infect Immun. 2005;  73 (8) 4478-4487
    CrossrefPubMedGoogle Scholar
  • 133 Liu D, Zhang D, Scafidi J, Wu X, Cramer C C, Davis III A E. C1 inhibitor prevents gram-negative bacterial lipopolysaccharide-induced vascular permeability.  Blood. 2005;  105 (6) 2350-2355
    CrossrefPubMedGoogle Scholar
  • 134 Horstick G, Heimann A, Götze O et al.. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion.  Circulation. 1997;  95 (3) 701-708
    CrossrefPubMedGoogle Scholar
  • 135 de Zwaan C, Kleine A H, Diris J H et al.. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction.  Eur Heart J. 2002;  23 (21) 1670-1677
    PubMedGoogle Scholar
  • 136 Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor.  Expert Opin Biol Ther. 2008;  8 (8) 1225-1240
    CrossrefPubMedGoogle Scholar
  • 137 Cichon S, Martin L, Hennies H C et al.. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.  Am J Hum Genet. 2006;  79 (6) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 138 Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema.  J Hepatol. 2002;  36 (5) 707-709
    CrossrefPubMedGoogle Scholar
  • 139 Cugno M, Nuijens J, Hack E et al.. Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with hereditary angioneurotic edema.  J Clin Invest. 1990;  85 (4) 1215-1220
    CrossrefPubMedGoogle Scholar
  • 140 Davis III A E. The pathophysiology of hereditary angioedema.  Clin Immunol. 2005;  114 (1) 3-9
    CrossrefPubMedGoogle Scholar
  • 141 Noga O, Brunnée T, Schäper C, Kunkel G. Heparin, derived from the mast cells of human lungs, is responsible for the generation of kinins in allergic reactions due to the activation of the contact system.  Int Arch Allergy Immunol. 1999;  120 (4) 310-316
    CrossrefPubMedGoogle Scholar
  • 142 Brunnée T, Reddigari S R, Shibayama Y, Kaplan A P, Silverberg M. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions.  Clin Exp Allergy. 1997;  27 (6) 653-663
    CrossrefPubMedGoogle Scholar
  • 143 Iwaki T, Castellino F J. Plasma levels of bradykinin are suppressed in factor XII-deficient mice.  Thromb Haemost. 2006;  95 (6) 1003-1010
    PubMedGoogle Scholar
  • 144 Shariat-Madar Z, Mahdi F, Schmaier A H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator.  J Biol Chem. 2002;  277 (20) 17962-17969
    CrossrefPubMedGoogle Scholar
  • 145 Bork K, Siedlecki K, Bosch S, Schopf R E, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema.  Mayo Clin Proc. 2000;  75 (4) 349-354
    CrossrefPubMedGoogle Scholar
  • 146 Bork K, Barnstedt S E. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema.  Arch Intern Med. 2001;  161 (5) 714-718
    CrossrefPubMedGoogle Scholar
  • 147 Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course.  Am J Med. 2006;  119 (3) 267-274
    CrossrefPubMedGoogle Scholar
  • 148 Castro-Magana M, Cheruvanky T, Collipp P J, Ghavami-Maibodi Z, Angulo M, Stewart C. Transient adrenogenital syndrome due to exposure to danazol in utero.  Am J Dis Child. 1981;  135 (11) 1032-1034
    PubMedGoogle Scholar
  • 149 Agostoni A, Bergamaschini L, Martignoni G, Cicardi M, Marasini B. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate.  Ann Allergy. 1980;  44 (5) 299-301
    PubMedGoogle Scholar
  • 150 Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients.  Medicine (Baltimore). 1992;  71 (4) 206-215
    CrossrefPubMedGoogle Scholar
  • 151 Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency.  J Allergy Clin Immunol. 1989;  83 (3) 677-682
    CrossrefPubMedGoogle Scholar
  • 152 Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A, Agostoni A. Hereditary angioedema: an appraisal of 104 cases.  Am J Med Sci. 1982;  284 (1) 2-9
    PubMedGoogle Scholar
  • 153 Waytes A T, Rosen F S, Frank M M. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.  N Engl J Med. 1996;  334 (25) 1630-1634
    CrossrefPubMedGoogle Scholar
  • 154 Prematta M, Gibbs J G, Pratt E L, Stoughton T R, Craig T J. Fresh frozen plasma for the treatment of hereditary angioedema.  Ann Allergy Asthma Immunol. 2007;  98 (4) 383-388
    CrossrefPubMedGoogle Scholar
  • 155 Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).  J Allergy Clin Immunol. 2007;  119 (6) 1497-1503
    CrossrefPubMedGoogle Scholar
  • 156 Kunschak M, Engl W, Maritsch F et al.. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema.  Transfusion. 1998;  38 (6) 540-549
    CrossrefPubMedGoogle Scholar
  • 157 Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema.  Transfusion. 2005;  45 (11) 1774-1784
    CrossrefPubMedGoogle Scholar
  • 158 Zuraw B L, Busse P J, White M et al.. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.  N Engl J Med. 2010;  363 (6) 513-522
    CrossrefPubMedGoogle Scholar
  • 159 Craig T J, Levy R J, Wasserman R L et al.. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.  J Allergy Clin Immunol. 2009;  124 (4) 801-808
    CrossrefPubMedGoogle Scholar
  • 160 Choi G, Soeters M R, Farkas H et al.. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.  Transfusion. 2007;  47 (6) 1028-1032
    CrossrefPubMedGoogle Scholar
  • 161 Zuraw B, Cicardi M, Levy R J, Nuijens J H et al.. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.  J Allergy Clin Immunol. 2010;  126 (4) 821-827
    CrossrefPubMedGoogle Scholar

Sacha ZeerlederM.D. Ph.D. 

Department of Immunopathology, Sanquin Research, Plesmanlaan 125

1066 CX Amsterdam, The Netherlands

Email: s.zeerleder@sanquin.nl

      >